MX2022005031A - Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas. - Google Patents

Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.

Info

Publication number
MX2022005031A
MX2022005031A MX2022005031A MX2022005031A MX2022005031A MX 2022005031 A MX2022005031 A MX 2022005031A MX 2022005031 A MX2022005031 A MX 2022005031A MX 2022005031 A MX2022005031 A MX 2022005031A MX 2022005031 A MX2022005031 A MX 2022005031A
Authority
MX
Mexico
Prior art keywords
lenalidomide
treatment
combination
lymphoma
leukemia
Prior art date
Application number
MX2022005031A
Other languages
English (en)
Inventor
Sumeet Ambarkhane
Johannes Weirather
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2022005031A publication Critical patent/MX2022005031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Abstract

La presente descripción está dirigida a una combinación terapéutica de un anticuerpo anti-CD19 y lenalidomida para el uso en el tratamiento de pacientes con cáncer hematológico. Además, la presente descripción hace referencia a la extensión de la supervivencia en general y/o la supervivencia sin progresión en pacientes que tienen tipos específicos de cánceres hematológicos.
MX2022005031A 2019-10-31 2020-10-30 Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas. MX2022005031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19206463 2019-10-31
PCT/EP2020/080492 WO2021084062A1 (en) 2019-10-31 2020-10-30 Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma

Publications (1)

Publication Number Publication Date
MX2022005031A true MX2022005031A (es) 2022-07-27

Family

ID=68424778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005031A MX2022005031A (es) 2019-10-31 2020-10-30 Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.

Country Status (12)

Country Link
US (1) US20210130460A1 (es)
EP (1) EP4051315A1 (es)
JP (1) JP2023501209A (es)
KR (1) KR20220103969A (es)
CN (1) CN114641312A (es)
AU (1) AU2020376305A1 (es)
BR (1) BR112022017162A2 (es)
CA (1) CA3159534A1 (es)
IL (1) IL292181A (es)
MX (1) MX2022005031A (es)
TW (1) TW202131948A (es)
WO (1) WO2021084062A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU729035B2 (en) 1997-06-12 2001-01-25 Novartis Ag Artificial antibody polypeptides
DE60234585D1 (es) 2001-02-27 2010-01-14 Us Government
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
EP2059536B1 (en) 2006-08-14 2014-01-08 Xencor, Inc. Optimized antibodies that target cd19
PL2066349T3 (pl) 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
WO2008150494A1 (en) 2007-05-30 2008-12-11 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
HUE054860T2 (hu) * 2016-05-30 2021-10-28 Morphosys Ag Eljárás betegekben CD19 elleni ellenanyagon alapuló terápia terápiás hasznosságának elõrejelzésére
US20220242952A1 (en) * 2019-05-03 2022-08-04 Morphosys Ag Anti-cd19 therapy in patients having a limited number of nk cells
WO2022117799A2 (en) * 2020-12-04 2022-06-09 Morphosys Ag Anti-cd19 combination therapy

Also Published As

Publication number Publication date
BR112022017162A2 (pt) 2022-10-18
JP2023501209A (ja) 2023-01-18
KR20220103969A (ko) 2022-07-25
AU2020376305A1 (en) 2022-05-12
TW202131948A (zh) 2021-09-01
IL292181A (en) 2022-06-01
WO2021084062A1 (en) 2021-05-06
US20210130460A1 (en) 2021-05-06
CA3159534A1 (en) 2021-05-06
CN114641312A (zh) 2022-06-17
EP4051315A1 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
JOP20200292A1 (ar) Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
WO2018210793A3 (en) ANTI-SIRPα ANTIBODIES
BR112016025437A2 (pt) combinação de lenalidomida e construto de polipeptídeo, e usos destes
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2010004164A (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma.
MX2020001727A (es) Terapia de combinacion.
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
PH12021550035A1 (en) Combination therapy
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2022005031A (es) Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.
MX2021011871A (es) Uso de virus oncoliticos en la terapia neoadyuvante del cancer.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
WO2019070161A3 (en) Articles and methods directed to personalized therapy of cancer
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2021011799A (es) Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.